EZH2 and prostate carcinoma: EZH2 overexpression was demonstrated for the first time in the context of prostate cancer [18] and later on observed in many other solid tumors such as breast, lung, hepatocellular, colorectal, and pancreatic cancers [19], as well as hematological cancers [20].